Limits...
Effect of NMSO3 treatment in a murine model of human metapneumovirus infection.

Spetch L, Bowlin TL, Casola A - J. Gen. Virol. (2008)

Bottom Line: BALB/c mice infected with human metapneumovirus (hMPV) were treated with the sulfated sialyl lipid NMSO3 (one dose of 50 mg kg(-1)) given at the time of infection.NMSO3 significantly reduced viral replication in the lungs, as well as hMPV-induced body weight loss, pulmonary inflammation and cytokine production, suggesting that antiviral treatment initiated at the beginning of viral infection can modify hMPV-induced disease.

View Article: PubMed Central - PubMed

Affiliation: Department of Pediatrics, University of Texas Medical Branch, Galveston, TX, USA.

ABSTRACT
BALB/c mice infected with human metapneumovirus (hMPV) were treated with the sulfated sialyl lipid NMSO3 (one dose of 50 mg kg(-1)) given at the time of infection. NMSO3 significantly reduced viral replication in the lungs, as well as hMPV-induced body weight loss, pulmonary inflammation and cytokine production, suggesting that antiviral treatment initiated at the beginning of viral infection can modify hMPV-induced disease.

Show MeSH

Related in: MedlinePlus

Effect of NMSO3 administration on hMPV-induced body weight loss. Mice were treated with 50 mg NMSO3 kg−1 at the time of hMPV infection (a) or at 24 h p.i. (b). The results show a representative diagram from three different experiments. All data points represent the means±sd of four to five animals.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC2800786&req=5

f1: Effect of NMSO3 administration on hMPV-induced body weight loss. Mice were treated with 50 mg NMSO3 kg−1 at the time of hMPV infection (a) or at 24 h p.i. (b). The results show a representative diagram from three different experiments. All data points represent the means±sd of four to five animals.

Mentions: Mice infected with 1×107 TCID50 hMPV lost 5–10 % of their original body weight, with a peak that occurred between days 1 and 2 p.i. They gradually returned to their original weight and then started to lose weight again for an additional 4–5 days before returning to baseline levels. Mock-infected mice did not loose weight (data not shown). HMPV-infected mice treated with NMSO3 showed a similar body weight loss in the first 3 days of infection; however, they did not loose additional weight after returning to baseline levels, as shown in Fig. 1(a).


Effect of NMSO3 treatment in a murine model of human metapneumovirus infection.

Spetch L, Bowlin TL, Casola A - J. Gen. Virol. (2008)

Effect of NMSO3 administration on hMPV-induced body weight loss. Mice were treated with 50 mg NMSO3 kg−1 at the time of hMPV infection (a) or at 24 h p.i. (b). The results show a representative diagram from three different experiments. All data points represent the means±sd of four to five animals.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC2800786&req=5

f1: Effect of NMSO3 administration on hMPV-induced body weight loss. Mice were treated with 50 mg NMSO3 kg−1 at the time of hMPV infection (a) or at 24 h p.i. (b). The results show a representative diagram from three different experiments. All data points represent the means±sd of four to five animals.
Mentions: Mice infected with 1×107 TCID50 hMPV lost 5–10 % of their original body weight, with a peak that occurred between days 1 and 2 p.i. They gradually returned to their original weight and then started to lose weight again for an additional 4–5 days before returning to baseline levels. Mock-infected mice did not loose weight (data not shown). HMPV-infected mice treated with NMSO3 showed a similar body weight loss in the first 3 days of infection; however, they did not loose additional weight after returning to baseline levels, as shown in Fig. 1(a).

Bottom Line: BALB/c mice infected with human metapneumovirus (hMPV) were treated with the sulfated sialyl lipid NMSO3 (one dose of 50 mg kg(-1)) given at the time of infection.NMSO3 significantly reduced viral replication in the lungs, as well as hMPV-induced body weight loss, pulmonary inflammation and cytokine production, suggesting that antiviral treatment initiated at the beginning of viral infection can modify hMPV-induced disease.

View Article: PubMed Central - PubMed

Affiliation: Department of Pediatrics, University of Texas Medical Branch, Galveston, TX, USA.

ABSTRACT
BALB/c mice infected with human metapneumovirus (hMPV) were treated with the sulfated sialyl lipid NMSO3 (one dose of 50 mg kg(-1)) given at the time of infection. NMSO3 significantly reduced viral replication in the lungs, as well as hMPV-induced body weight loss, pulmonary inflammation and cytokine production, suggesting that antiviral treatment initiated at the beginning of viral infection can modify hMPV-induced disease.

Show MeSH
Related in: MedlinePlus